Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Ibnsina Pharma's Enterprise Value is E£20,091 Mil.
Ibnsina Pharma's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 was E£887 Mil. Therefore, Ibnsina Pharma's EV-to-FCF for today is 22.66.
The historical rank and industry rank for Ibnsina Pharma's EV-to-FCF or its related term are showing as below:
CAI:ISPH'
s EV-to-FCF Range Over the Past 10 Years
Min: -430.37 Med: -5.76 Max: 81.48
Current: 22.66
During the past 10 years, the highest EV-to-FCF of Ibnsina Pharma was 81.48. The lowest was -430.37. And the median was -5.76.
CAI:ISPH's EV-to-FCF is ranked worse than 61.11% of 72
companies
in the Medical Distribution industry
Industry Median: 17.415
vs CAI:ISPH: 22.66
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Ibnsina Pharma's PE Ratio (TTM) for today is calculated as:
Ibnsina Pharma's share price for today is E£11.73.
Ibnsina Pharma's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was E£0.830.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Ibnsina Pharma EV-to-FCF Related Terms
Ibnsina Pharma EV-to-FCF Historical Data
* Premium members only.
The historical data trend for Ibnsina Pharma's EV-to-FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Distribution subindustry, Ibnsina Pharma's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Ibnsina Pharma EV-to-FCF vs Medical Distribution Industry
For the Medical Distribution industry and Healthcare sector, Ibnsina Pharma's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Ibnsina Pharma's EV-to-FCF falls into.
Ibnsina Pharma's current Enterprise Value is E£20,091 Mil.
Ibnsina Pharma's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was E£887 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Ibnsina Pharma (CAI:ISPH) has a EV-to-FCF of 22.66 as of Jul. 23, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Ibnsina Pharma and its competitors. According to the industry distribution chart, Ibnsina Pharma ranks #44 out of 72 companies in the Medical Distribution industry, placing it in the top 61.1%.
Is Ibnsina Pharma's EV-to-FCF too high?
Ibnsina Pharma's current EV-to-FCF is 22.66. The Medical Distribution industry median EV-to-FCF is 17.42. Ibnsina Pharma's value of 22.66 is 30.1% above this industry median. Based on the distribution chart, Ibnsina Pharma ranks #44 out of 72 companies in the Medical Distribution industry, which is below the industry midpoint. Overall, Ibnsina Pharma has a GF Score™ of 86/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Ibnsina Pharma's EV-to-FCF compare to MCK and CAH?
According to the Medical Distribution industry distribution chart, Ibnsina Pharma ranks #44 out of 72 companies for EV-to-FCF. This places Ibnsina Pharma in the lower half of its industry. The industry median EV-to-FCF is 17.42. Ibnsina Pharma's value of 22.66 is 30.1% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Medical Distribution company?
The median EV-to-FCF among Medical Distribution companies is 17.42, based on 72 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Ibnsina Pharma's current EV-to-FCF of 22.66 is 30.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Ibnsina Pharma and its competitors. For the Medical Distribution industry, the median EV-to-FCF is 17.42 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Ibnsina Pharma's current EV-to-FCF is 22.66. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ibnsina Pharma stock overvalued right now?
Based on GuruFocus' analysis, Ibnsina Pharma (CAI:ISPH) is currently considered Modestly Overvalued. The stock's GF Value™ is E£10.56, compared to a current price of E£11.73 — trading 11.1% above its estimated fair value. The current EV-to-FCF is 22.66 and 30.1% above the Medical Distribution industry median of 17.42. Ibnsina Pharma's overall GF Score™ is 86/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For Ibnsina Pharma (CAI:ISPH), the current EV-to-FCF is 22.66 as of Jul. 23, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Ibnsina Pharma (CAI:ISPH) Overvalued in 2026?
Based on GuruFocus' analysis, Ibnsina Pharma stock appears to be overvalued.
The current stock price of E£11.73 is trading 11.1% above its estimated GF Value™ of E£10.56.
GuruFocus considers Ibnsina Pharma to be Modestly Overvalued.
Key valuation signals for CAI:ISPH:
EV-to-FCF: 22.66
GF Value™: E£10.56 vs. price of E£11.73 (11.1% above fair value)
Industry Position: 30.1% above the Medical Distribution median (#44 of 72)
No single metric tells the full story. See the CAI:ISPH stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Ibnsina Pharma is an Egypt-based pharmaceutical distribution company. It is engaged in purchasing and selling in wholesale and distribution of pharmaceutical, semi- pharmaceutical, and cosmetic products. It distributes a portfolio of pharmaceutical products from local and multinational pharmaceutical companies to retail pharmacies, wholesalers, hospitals, and public health institutions. In addition, the company also offers services including warehousing and logistics, marketing solutions, importation, packaging, market research, and analysis.
86GF Score
Get the complete analysis for CAI:ISPH
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CAI:ISPH has been successfully added to your 
